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Osteosarcoma is a rare tumor diagnosed at any age; however younger age is a common risk23
factor. In addition, multiple factors are believed to contribute to higher rates of osteosarcoma,24
particularly race and gender. Although diagnosed worldwide, osteosarcoma is found to be more25
prevalent in Africa with high numbers of cases reported in Nigeria, Uganda, and Sudan.26
Additionally, higher rates are detected in African Americans, suggesting a genetic predisposition27
linked to race. This review focuses on identifying high risk factors of osteosarcoma with an28
emphasis on sarcoma epidemiology and risk factors in African countries.29
30
1 Introduction31
Osteosarcoma is a primary bone tumor, characterized by deposition of an immature osteoid32
matrix (1). The incidence rates vary depending on age, race, sex and a number of other factors.33
The rates vary throughout the world from 3-5 per million in males to 2-4 per million for females34
(2). In general is around 5.2 for children aged 0-19 years, per year per millions of people (3). It is35
ranked the eighth highest childhood cancers at around 2.4% of tumors diagnosed. Despite being36
a rare type of tumor, a number of risk factors have been identified, including race and sex; with37
indigenous African and African American males being disproportionately more affected (4). Age38
is also a key factor with those aged 10-14 years old most likely to be affected and a second peaks39
occurring at adults older than 65 years old (2, 5, 6). Treatment usually concentrates on surgery to40
remove the tumor and metastasis, often in combination with chemotherapy (7). Surgery may41
involve limb amputation or limb salvage techniques depending on the grade of tumor. Over the42
years many differing treatment protocols and in vitro and in vivo models have been described43
and developed. In addition, work into immunotherapy-based treatments and pharmacogenomics44
has been undertaken but to date outcomes for patients diagnosed with high grade osteosarcoma45
remain poor (8-10). Given this, it is essential to conduct research further exploring key risk46
factors to understand the pathogenesis of the disease and to develop more effective treatment47
plans, which is the primary focus of the current review.48
Clinically, osteosarcoma can be divided into two stages: localized and metastatic. Localized49
osteosarcoma refers to the cancer, affecting only the bone and the tissues in which it developed.50
It can then further be split into resectable and non-resectable stages, based on the viability of51
surgically removing the tumor. The metastatic stage of osteosarcoma shows that the cancer has52
spread from the original site to other organ sites, making it more difficult to treat.53
The two most common classification systems, used in this review, are the Enneking Staging54
System and Broder’s classification. The named classification systems are important in treatment55
planning, providing insight into prognosis, assisting in evaluating treatment results, facilitating56
effective inter-institutional communication, and contributing to investigation of human57
malignancies (Jawad and Scully 2010). The Enneking Staging System includes benign and58
malignant mesenchymal tumors such as osteosarcoma (11). This system includes three categories59
for benign tumors: latent, active, and aggressive. With regards to malignant tumors, the60
Enneking Staging System considers grade (G1, G2), local extent of tumor (T, T1, T2), and the61
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presence or absence of metastasis (M0, M1). Stage I includes low-grade (G1) and62
intra/extracompartmental tumors (T1 and T2) without metastasis (M0). Stage II tumors are63
characterized by high-grade (G2) and intra/extracompartmental tumors (T1 and T2) without64
metastasis. Stage III includes any grades and any sites with regional and distant metastasis (11).65
While the Enneking Staging System characterizes benign and malignant tumors, Broder’s66
classification focuses specifically on classifying the differentiations in squamous cell carcinomas67
(11, 12). According to Broder’s classification, tumor grades from 1 to 4 reflect the presence of68
anaplasia. Low-grade tumors are characterized by low mitotic rates, low nuclear to cytoplasmic69
ratio, and limited pleomorphism. However, high-grade lesions (3 and 4) have a higher incidence70
of metastasis and are characterized by mitosis, prominent nucleoli, and pleomorphism (13).71
Generally, metaphysis of the long bones is the most common site of origin for osteosarcoma in72
adults (14), with femur (42%), tibia (19%) and humerus (10%) frequently found to be affected73
by the tumor (Figure 1). Other less frequent locations include the skull or jaw (8%) and pelvis74
(8%) (14). While osteosarcoma is most common in the long bones of the extremities, in older75
patients other bones are also identified as tumor sites. Cranial, facial, and axial tumors increase76
in frequency with age, with about 40% of all osteosarcomas localized in patients aged 60 years77
or older (4). The overall 5-year survival rate for osteosarcoma is 70% (4, 14), which varies78




The pathogenesis of osteosarcoma remains largely unknown; however, correlation between bone83
growth during childhood/puberty and tumor risk diagnosis suggest that growth factors could play84
a role in the onset of the disease (15, 16). Osteoid is commonly found in osteosarcoma,85
suggesting that osteoblasts can be involved in the tumor development (17). However, genetic and86
epigenetic changes in osteosarcoma cells imply their primitive origin (18-20). Another important87
feature of these cells is their ability to differentiate into multiple cell types including osteoblasts88
(21). There are currently two primary competing hypotheses regarding the cellular origin of89
osteosarcoma: mesenchymal stem cell (MSC) and the osteoblast (22-25). Both hypotheses are90
based on results from in-vitro and in-vivo studies.91
The MSCs origin of osteosarcoma is supported by findings indicating that genetic mutations in92
progenitors are linked to failure of osteoblast maturation and development of osteosarcoma-like93
tumors in animal models. Spontaneous transformation of MSCs is shown to promote formation94
of osteosarcomas in animal models (26, 27). The malignant transformation of MSCs is95
accompanied by accumulation of chromosomal instability and various mutations (28, 29).96
Additionally, the Rb1 gene deletion in MSCs causes overexpression of c-MYC, which could97
promote the osteosarcoma-like properties and express osteosarcoma markers CD99, ALP,98
osteonectin, and osteocalcin (30). These MSCs also metastasize into the lung, which is a key99
clinical feature of osteosarcoma in humans.100
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Supporters of the osteoblast origin of sarcoma argue that osteoblasts, obtained from101
osteosarcoma patients, and not MSCs, maintain in-vitro and in-vivo tumorigenesis, thus playing102
a role in the pathogenesis of osteosarcoma (22). Supporting this notion, activation of the103
intracellular domain of Notch1 in transgenic mice promotes immature osteoblast proliferation104
and induces osteosarcomagenesis (31). Both MSCs and osteoblast hypotheses can explain105
pathogenesis of osteosarcoma. It is possible that both cell types contribute to tumor onset.106
Osteosarcoma can metastasize by dissemination through the circulatory route. Lungs are the107
most common site of metastasis (32). The survival rate of osteosarcoma patients with lung108
metastases remains low, even when metastases are surgically removed (33). However, there is109
evidence suggesting that resection of pulmonary metastases improves the survival of these110
patients (34, 35). In contrast, other studies demonstrate that chemotherapy has limited effect on111
the prognosis of osteosarcoma outcome in patients with lung metastasis (36). Major setbacks of112
chemotherapy are based on low tumor cell sensitivity to the treatment and subsequent side113
effects (37, 38). Patients with lung metastasis have a higher risk of tumor relapse and fatal114
outcome (39, 40). Axial locations with a tumor diameter larger than 5 cm were linked to a higher115
risk of lung metastasis.116
3 Epidemiology117
Osteosarcoma is diagnosed worldwide, however incidence rates vary in different countries and118
populations. In the United States, osteosarcoma occurrence was reported to be higher in young119
Asian/Pacific Islander and black patients (average rates of 5.3 and 5.1 respectively for 0-24 year120
olds) in comparison to non-Hispanic White, Hispanic and American Indian/Alaska Native121
populations which saw rates of 3-4.9 per million (4). A similar trend is documented among the122
younger age groups in South Europe (Stiller et al., 2009), especially in Italy (41). While123
confirming the high rate of osteosarcoma in Italy, Mirabello et al. reported even higher numbers124
of cases diagnosed among Latin populations (rates of 7.0–7.6 for males and 3.5–4.9 for females).125
This work also highlighted particularly high incidence levels in the Philippines and Ecuador126
(rates up to up to 11.4 and 8.2 respectively)(2). Interestingly, overall a high incidence of127
osteosarcoma was reported in African countries, predominantly in Sudan and Uganda, as128
compared to those in Europe (2, 41).129
In the United States, osteosarcoma was more often diagnosed in children and adolescents who130
were Asian/Pacific Islander, followed by African American (age 25–59 years), and Caucasian131
(age 60+ years)(42). In two consecutive studies conducted by the National Cancer Institute132
SEER Program, higher annual rates of osteosarcoma in children and young adolescents were133
found in African American populations, while lower rates were present among Caucasian134
Americans, based on data published for the years 1975–1995 (43). In a more recent study, an135
increased number of osteosarcoma incidence was again detected in African Americans, as well136
as Hispanics, compared to Caucasian American populations (44). Similar trends persisted in137
older age groups, with a higher rate of osteosarcoma diagnosis reported in African Americans as138
compared to Caucasians (45). This was supported by rates of 4.6 cases per million people in139
Black people compared to 3.7 for non-Hispanic White, 3.0 for Hispanic people, 2.9 in American140
Indian/Alaska Native and 1.9 for Asian/Pacific Islanders aged 60+ years old (4). It is important141
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to note that the highest incidence in this report was Asian/Pacific Islanders when aged 0-24 but142
by 25-59 and 60+ years they represented the least likely group to be affected.143
It appears that juvenile osteosarcoma is more often diagnosed in South Europe, Africa, Asia,144
South America, and the Pacific Islands, while late age of tumor onset is more prevalent in145
Northern Europe, US, and Australia (2). Mirabello et al. suggested that osteosarcoma in elderly146
patients could be a result of malignant transformation of Paget's disease (2). To support this147
argument, the authors discussed a striking geographic variation in the prevalence of Paget's148
disease. High prevalence of the disease is documented in the United Kingdom, Australia, and149
North America, with a lower frequency present in Asia and the Middle East (46, 47). This150
distribution is consistent with osteosarcoma diagnosis in elderly populations.151
While most available data on disease epidemiology comes from industrially developed countries,152
there is very little information about the rest of the world, including Africa. This can skew the153
results of studies that compare disproportionally larger data sets from more developed countries154
with smaller data sets from other countries. There are, however, a few studies that prioritize155
underrepresented countries. In a comprehensive study by Parkin et al., the systematic review of156
childhood cancers focused exclusively on three African countries: Nigeria, Uganda, and157
Zimbabwe (41). The overall cancer incidence rate in African countries was the lowest as158
compared to the rest of the world. However, when incidence rates of individual tumors were159
analyzed, osteosarcoma cases appeared high in Nigeria and Uganda (Figure 2). High rates of160
osteosarcoma were also reported among African Americans, suggesting the presence of a genetic161
predisposition linked to the race of the patient. Furthermore, the relative frequency of162
osteosarcoma in African countries was higher (Sudan 5.3% and Uganda 6.4%) when compared163
to European countries (2%-3%). In a more recent study, Aina et al. demonstrated that primary164
bone tumors accounted for 1.26% of the total malignant neoplasms diagnosed between 1991 and165
2003 in Ile-Ife, South West Nigeria (48). This frequency is similar to that reported in Ibadan166
(1.28%), another province in South West Nigeria (49). However, relatively higher osteosarcoma167
rates were demonstrated in Zaria, Northern Nigeria (3.6%) (50), and Kenya (2.5%) (51).168
In the analysis of 117 patients with primary bone tumors, Pillay et al. revealed that osteosarcoma169
was the most common primary malignant bone tumor, accounting for 72.6% of all cases170
admitted to the Department of Orthopaedic Surgery, Grey’s Hospital, South Africa (52). In171
accordance with findings reported in previous studies, the authors also confirmed the higher male172
to female ratio and younger age of patients, (4, 28, 53, 54). In addition, Pillay et al identified173
that osteosarcoma is diagnosed in African patients at a much younger age (18 years Nigeria; 25174
years South Africa), compared to patients from the USA (36 years) and United Kingdom (40175
years) (52, 55). A decade-long multicenter analysis of bone tumor incidence in Cameroon176
showed that osteosarcoma was the most frequent form of primary malignant bone tumor (56).177
The authors suggested that the high incidence rate of osteosarcoma in young patients could be178
explained by the larger proportion of young people in the population, where 56% of179
Cameroonian citizens are children or teenagers, and only 4% are elderly (56). A number of other180
hospital-based cross-sectional studies, conducted in Nigeria, Ethiopia and Northern Tanzania181
similarly reported it being predominantly diagnosed in young patients (57). Notably, many182
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patients in Tanzania were admitted to the hospital with advanced stages of metastatic183
osteosarcoma only after seeking help from a local healer first.184
4 Risk factors185
4.1 Age. Osteosarcoma is characterized by bimodal age distribution, with the first diagnosis186
peak associated with young children and adolescents, and the second peak documented in187
geriatric patients (54). While the early age incidence rate of osteosarcoma diagnosis is relatively188
consistent around the world (3 to 4.5 cases/million population/year) (2, 53, 54, 58), more189
variations (1.5 to 4.5 cases/million population/year) were documented among ages of 60 and190
over (2, 4). Even though the patient’s age is generally agreed to be one of the risk factors and a191
potential prognostic marker for osteosarcoma, it cannot be applied to the African population due192
to inaccurate or unavailable demographic data (59). Many of the studies show incidence for older193
patients but most show a 60+ years rate. Average incidence rates of 1-7 have been observed in194
males aged 75+ worldwide some countries such as Australia, Canada and the UK saw even195
higher levels (15-18, 10-11 and 11.6 respectively) (2).196
4.2 Gender. Multiple studies, including of the African population, have demonstrated a197
gender-specific osteosarcoma association, stronger pronounced among males, than females (4,198
43, 45, 49, 60-62). It has also been reported that females under the age of 15, have slightly higher199
cancer rates than males in the same age group (4, 41, 42, 63-68). In adolescents, incidence peaks200
at a later age and is higher among males (age 15–19, peak rate of 9–15 cases/million population)201
compared to females (age 10–14, peak rate of 6–10 cases/million population) (4, 41), suggesting202
that bone growth, hormonal changes, and/or development associated with puberty may be203
involved in osteosarcoma etiology. In elderly patients, osteosarcoma prevails among African204
Americans (42) and females, particularly those with a prior history of cancer (4). In general the205
older age groups (60+ years old) also show less disparity between the sexes, with male-to-female206
ratios of 1.01:1(2) worldwide and 0.9:1 in the United States. This increases to 1.43:1207
(male:female) in those under 24 years old and 1.28:1 in those aged 25-59. This data may further208
support the pubertal changes theories in relation to younger patients.209
4.3 Socio-economic status. It appears that patients from lower socioeconomic groups have210
higher incidence rates of osteosarcoma and mortality (69). Socioeconomic status, including211
education, income, and occupation, was shown to be a strong predictor of morbidity and212
mortality, with education having the strongest impact on the patient’s survival. Individuals and213
caregivers with low or lack of education may have difficulty in understanding the full214
seriousness of the disease. This can cause delays in seeking or refusal of medical attention in215
favor of such alternative methods as local bonesetters. Traditional bonesetters are commonly216
preferred by locals for treating many musculo-skeletal diseases, however, 34% patients withdrew217
from treatment according to Oboirien et al.’s study from West Nigeria due to the “lack of218
improvement” (60). Since many patients are living in rural areas, traditional bonesetters are often219
the only available and affordable source of treatment in that region (Oboirien and Khalid 2013).220
Therefore, educating traditional bonesetters in bone tumor awareness is essential to improving221
survival rates among osteosarcoma patients.222
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4.4 Height. The earliest observation of positive correlation between patient’s height and risk223
of osteosarcoma was published by Fraumeni in the 60-s (61) and was later confirmed by multiple224
studies (62, 64, 65). Meta-analysis demonstrated that “taller-than-average” and “very tall”225
individuals are at an increased risk of developing osteosarcoma (66). The same study also226
showed that individuals with high birth weights had increased risks. Furthermore, Longhi et al.227
showed a strong correlation between height and osteosarcoma diagnosis in growing individuals228
(64). These correlations suggest that growth factors and/or rapid bone growth both in puberty229
and in utero could play a role in the cancer pathogenesis.230
4.5 Genetics. The etiology of osteosarcoma is complex and not well understood. Studies231
have identified several genetic risk markers, including hereditary retinoblastoma (Rb) (67, 68),232
Rothmund–Thomson syndrome (70, 71), and Li Fraumeni syndrome (72). Mutations in the Rb233
gene have a strong association with predispositions to osteosarcoma (73-75), where the loss of234
heterogeneity in the Rb gene could indicate unfavorable disease outcome (76). Additionally,235
altered p53 loci was reported in 10–39% of osteosarcoma cases (77-80). Combined mutations in236
Rb and p53 show synergistic tumorigenic properties (79, 81, 82).237
It appears that osteosarcoma is associated with a rapid genotype modification, complicating the238
identification of potential therapeutic targets (83, 84). Nevertheless, a variety of macromolecular239
biomarkers with potential clinical implications have been identified including ErbB-2 (85, 86),240
cathepsin D (87), FBXW7 (88), and miR-421 (89). However, as of yet, the true diagnostic,241
etiologic, and clinical significance of these biomarkers is ongoing and controversial.242
4.6 Environmental factors. Environmental conditions were also named as risk factors of243
osteosarcoma. Vu et al. have shown that the risk of osteosarcoma is a linear function of local244
doses of radiation (90). Similar data was presented by Arlen et al., who showed that residents of245
areas with radiation ranging from 1,200 rads/few weeks to 24,000 rads/2 years were more likely246
to develop osteosarcoma (91). Additionally, a link between radiation exposure and osteosarcoma247
was reported among radium dial workers (92). Accordingly, treatment using teriparatide, a248
parathyroid hormone peptide, was suggested to increase the risk of radiation-induced249
osteosarcoma (93). Bassin et al. also proposed that exposure to fluoridated water was a potential250
risk factor for osteosarcoma (94). Similar observations were published by Gandhi et al., which251
suggested that fluoride-induced oxidative and inflammatory stress contribute to the pathogenesis252
of osteosarcoma (95). Other chemical risk factors include methylcholanthrene and chromium253
salts (96), beryllium oxide (97), zinc beryllium silicate (98), asbestos, and aniline dyes (99).254
5 Conclusion255
Osteosarcoma is a rare tumor, more often diagnosed among young patients. Multiple factors256
have been shown to contribute to developing osteosarcoma, most commonly race, gender and257
age. A higher incidence rate of the diagnosis is registered among young males of African origin,258
which was supported by the research findings conducted in Nigeria, Uganda, and Sudan.259
Additionally, high cancer rates are detected among African Americans, suggesting genetic and260
racial predispositions to osteosarcoma. Identifying genetic markers is essential to developing261
novel therapeutics and diagnostics. Further studies on osteosarcoma genetic markers among the262
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Figure Legends270
Figure 1. Osteosarcoma locations within the skeleton.271
Figure 2. Osteosarcoma in Africa. The frequency rate of osteosarcoma in Sudan (5.3%), Nigeria272
(3.6% - 1.28%), Uganda (6.4%), Kenia (2.5%), Tanzania (61%), Cameroon (39%), Zambia273
(55.3%), Rwanda (8.2%) and South Africa (72.6%).274
275
Contribution to the Field276
Osteosarcoma is a rare tumor, which affects young and elderly patients. Incidence rates not only277
change with age but also with race and gender. Males living in parts of Africa are more likely to278
be affected, as are African Americans, thus indicating a potential genetic predisposition. Other279
races have differing incidence rates but some change depending on the age and gender of the280
patient group. This review also looks at the treatments, genetic markers and the ongoing work to281
develop therapeutics and diagnostic techniques. It also highlights the need for more research into282
differing populations and environmental factors in relation to osteosarcoma risk.283
284
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